Human carbonic anhydrase II (CA II), a zinc metalloenzyme, was screened against 960 structurally diverse, biologically active small molecules. The assay monitored CA II esterase activity against the substrate 4-nitrophenyl acetate in a format allowing high-throughput screening. The assay proved to be robust and reproducible with a hit rate of ∼2%. Potential hits were further characterized by determining their IC 50 and K d values and tested for nonspecific, promiscuous inhibition. Three known sulfonamide CA inhibitors were identified: acetazolamide, methazolamide, and celecoxib. Other hits were also found, including diuretics and antibiotics not previously identified as CA inhibitors, for example, furosemide and halazone. These results confirm that many sulfonamide drugs have CA inhibitory properties but also that not all sulfonamides are CA inhibitors. Thus many, but not all, sulfonamide drugs appear to interact with CA II and may target other CA isozymes. The screen also yielded several novel classes of nonsulfonamide inhibitors, including merbromin, thioxolone, and tannic acid. Although these compounds may function by some nonspecific mechanism (merbromin and tannic acid), at least 1 (thioxolone) appears to represent a genuine CA inhibitor. Thus, this study yielded a number of potentially new classes of CA inhibitors and preliminary experiments to characterize their mechanism of action. (Journal of Biomolecular Screening 2006:782-791) 
INTRODUCTION

C
ARBONIC ANHYDRASES (CAs) are metalloenzymes that catalyze the reversible interconversion of carbon dioxide and bicarbonate (equation 1): (1) CAs have roles in carbon metabolism, human health, and the global carbon cycle and are found in most eukaryotic and many microbial organisms. 1 There are 5 known CA structural families, the α, β, and γ classes, and the recently discovered δ and ε classes.
1,2 The zinc-dependent α-class CAs are the most medically relevant, including at least 14 known isoforms in mammals 2 and structurally similar isozymes in human pathogens, for example, Helicobacter pylori 3 and Plasmodium falciparum. 4 CA II is catalytically the fastest member of the α-class CA family, exhibiting near-diffusion-limited kinetics. 5 The catalytic mechanism and inhibition of CA II has been intensively investigated. Catalytically active α CAs contain an active site zinc ion (Zn 2+ ) coordinated by 3 histidine residues. During catalysis, the zinc ion functions as a nucleophilic Lewis acid, lowering the pK a of a bound water molecule, thus forming a reactive hydroxide ion. 6 Some of the catalytically active α CAs can also catalyze the hydrolysis of esters, for example, 4-nitrophenyl acetate (4-NPA) 7, 8 via a zinc-hydroxide mechanism. Known α-CA inhibitors (CAIs) include various anions, imidazole, phenol, hydroxyurea, carboxylates, organic phosphates and phosphonates, and various sulfonamide compounds (R-C-SO 2 NH 2 ).
for example, sulfamates (R-OSO 2 -NH 2 ), hydroxysulfonamides (R-SO 2 NH(OH)), and hydroxamates (R-CO-NH-OH). 2, 10 Mammalian α-CA isozymes have important physiological functions, including bicarbonate transfer, and are the targets of drugs treating various diseases, including glaucoma, highaltitude sickness, hypertension, congestive heart failure, gastric and duodenal ulcers, epilepsy, memory function, and osteoporosis. 9, 11 Recent reports also suggest a functional role for several CA isozymes in certain types of cancers, in particular, the CA IX and CA XII isozymes. 12 Α physiological role in malarial infections has also recently been postulated for α CAs, and at least 3 α-CA isozymes have been identified in P. falciparum. 4 There are issues with currently marketed sulfonamide drugs, possibly because of their lack of specificity, which results in undesirable side effects. 13 In addition, a significant fraction of patients show allergic responses to some sulfonamides. 14 Other drugs, originally not classified as CAIs (e.g., the cyclooxygenase-2 [COX-2] inhibitors celecoxib and valdecoxib, 15 the anticonvulsant drugs topiramate 16 and zonisamide, 17 and antipsychotic drugs such as sulpiride 18 ), are reported to have CAI activity. Thus, the discovery of nonsulfonamide CAIs could lead to the development of novel therapeutic treatments.
Here, the hypothesis that a high-throughput screen (HTS) of diverse biologically active compounds could yield new structural insights into CA inhibition and identify new inhibitors for this enzyme was experimentally tested. A colorimetric assay for the 4-NPA esterase activity 19 was adapted to a high-throughput format and used to screen the Genesis Plus (GenPlus) library of compounds. This strategy of screening biologically characterized compounds (i.e., "old" drugs on "new" targets) has been described previously. 20 Thus, this report describes the use of HTS to test ligand interaction with CA II, resulting in the identification of at least 2 novel classes of CAIs. Detailed mechanismof-action studies of these novel classes of inhibitors will be reported subsequently.
MATERIALS AND METHODS
CA II protein expression and purification
The human CA II enzyme, cloned under the control of the inducible T7 promoter in the plasmid pACA, was a generous gift from Dr. Carol Fierke, University of Michigan. The enzyme was expressed by growing Escherichia coli BL21 DE3 cultures in Luria-Bertani media, at 37 °C shaken at 225 rpm to an OD 600 of 0.5 to 0.8, followed by induction with 0.1 mM IPTG for 3 h. Cells were lysed in 20 mM, pH 7.5 Tris buffer containing 1.0 mg/ml lysozyme, 5 µg/ml deoxyribonuclease I, 5 mM MgSO 4 , with stirring, on ice, for 30 min. The lysate was clarified by centrifugation at 8000g for 15 min and loaded onto an SP Sepharose Fast Flow cation exchange column (Amersham Biosciences, Piscataway, NJ). CA II was eluted with a 0 to 1.0 M NaCl gradient. Fractions containing CA II (assessed to be >95% pure by sodium dodecyl sulfate polyacrylamide gel electrophoresis) were concentrated using a Centricon device with a YM-10 membrane (Millipore, Billerica, MA), then frozen in liquid nitrogen and stored at -80 °C until use. CA II protein concentration was determined using a molar absorptivity of 5.4 × 10 4 M -1 cm -1
.
Compound library
The GenPlus collection was purchased from MicroSource Discovery Systems (Gaylordsville, CT; http://www.msdiscovery .com/download.html). Stock solutions of compounds (10 mM in DMSO) were stored at -80°C until use. A CCS Packard PlateTrak (PerkinElmer, Shelton, CT) robotic pipetting station was used to dilute the compounds with DMSO to a final 2-mM concentration in Costar 3365 96-well polypropylene roundbottom storage plates (Corning, Acton, MA) for use as working "daughter" plates. All daughter plates used for both screening and follow-up assays were hand sealed with Costar 6570 aluminum self-adhesive lids for storage at -20 °C.
Esterase activity screening assay
The catalytic activity of human CA II was monitored by the hydrolysis of the nonphysiological but commercially available ester, 4-NPA (Sigma-Aldrich, St. Louis, MO). The products of the hydrolysis reaction are acetate and nitrophenolate, which ionize to give a bright yellow anion that is detected by measuring its absorbance at 348 to 400 nm with a SpectraMax Plus 384 ultraviolet-visible spectrophotometer (Molecular Devices, Sunnyvale, CA) using 96-well plates.
For initial screens, 100 µl of assay solution containing 1 µM purified CA II in 50 mM, pH 7.5 MOPS, 33 mM Na 2 SO 4 , 1.0 mM EDTA buffer was dispensed into flat-bottom 96-well plates (Costar 3370) with a Matrix Impact 2 P1250 pipettor (Matrix Technologies, Hudson, NH) or a Multidrop peristaltic dispenser (MTX Lab Systems, Vienna, VA) depending on the number of plates to be screened. Each compound plate was tested in triplicate. Daughter compound plates containing compounds at 2 mM were thawed, and 1 µl was then transferred, using the PlateTrak, into the assay solution. Compounds were allowed to equilibrate with the enzyme for 15 min at room temperature. On each plate, the CA II inhibitor, acetazolamide, was added in duplicate (10 µM final concentration) as a positive control (100% inhibition), and 100% DMSO was included as a negative control (0% inhibition). The reaction was initiated by addition of 10 µl of 5 mM 4-NPA solution in 10% DMSO, 90% assay buffer with a Multidrop dispenser, and data collection was started. The absorbance of each well was measured at 348 nm every 12 to 15 s for 5 min with the SpectraMax Plus 384 microplate spectrophotometer, running SoftMax Pro software. These conditions give an initial substrate concentration of 450 µM 4-NPA and a total, final volume of 111 µl per well and an 18 µM final compound Carbonic Anhydrase II Inhibition Profiling concentration. The final DMSO concentration in this assay was 1.8% (v/v), which did not appear to interfere with CA II enzyme activity or specificity. The initial velocities, determined by the SoftMax Pro software, were normalized to a scale of 0% to 100% inhibition with an MS Excel spreadsheet, using the controls on each plate.
Inhibitor IC 50 measurement
The enzyme concentration (1 µM), assay plates, and buffer composition were identical to those used in the initial screen. Hits identified in the initial screen were dissolved at 10 mM in DMSO and serially diluted 1:2 with DMSO in round-bottom 96-well polypropylene plates (Costar 3365). The IC 50 assays were determined in quadruplicate, using 2 duplicate rows of each plate for a compound, with 2 replicate assays performed for each plate.
Each compound of interest was tested for nonspecific, promiscuous inhibition 21 by testing in the presence and absence of 0.01% Triton X-100 to identify hits possibly acting by formation of colloidal aggregates of lipophilic compounds. The influence on CA II enzyme concentration on the Hill slope and IC 50 values was also investigated using a 5-fold higher enzyme concentration (1 µM v. 5 µM).
The normalized data were then fit to the 4-parameter nonlinear sigmoidal dose-response model (equation 2) using GraphPad Prism version 4.0 software to obtain the IC 50 and Hill slope: (2) where I min is the minimum signal, I max is the maximum signal, and X is the concentration of inhibitor.
Inhibitor K d measurement
An assay monitoring competitive displacement of a fluorescent CA II inhibitor, dansylamide (DNSA), was used to further characterize actives. DNSA is virtually nonfluorescent in aqueous solution; however, upon binding to CA II and excitation at 280 nm, it fluoresces at 470 nm. 22 The dissociation constants (K d ) of screening hits were determined using essentially the method of Baird et al., 23 except that experiments were determined using black, flat-bottom 96-well plates (Costar 3915) and a BMG Technologies Polarstar fluorescence microplate reader (BMG Labtech, Durham, NC) with 280-and 470-nm fixed wavelength filters. The K d value for DNSA was determined by titrating 100 nM CA II with varying concentrations of DNSA, ranging from 97 nM to 99 µM in a total assay volume of 101 µl. The equilibrium dissociation constant for DNSA (K DNSA ) was then determined by fitting the data to equation 3 using KaleidaGraph version 4.0 software. (3) where F tot is the total fluorescence, F ini is the initial fluorescence of CA II in the absence of DNSA, and F end is the endpoint fluorescence. The equilibrium dissociation constants for other compounds were determined by competitive binding with DNSA. A fixed concentration of 20 µM DNSA and 100 nM CA II was then titrated against inhibitor from 47 pM to 99 µM. The K d value of each inhibitor was then determined by fitting the data to equation 4 with KaleidaGraph ( Table 1) : (4) where F tot is the fraction of total fluorescence, F obs is the fluorescence signal at any concentration of inhibitor, F ini is the initial fluorescence of CA II without DNSA, and F end is the end-point fluorescence.
RESULTS
Assay reproducibility
The reproducibility of the screening assays was assessed by the Z′ factor 24 
where σ c+ is the standard deviation of the positive control for the assay, σ c-is the standard deviation for the negative control, and (µ c+ -µ c-) define the mean values for the positive and negative controls. The Z′ values for individual plates used in the screen were all greater than 0.7 (Fig. 1) ; the average Z′ for all 36 plates was 0.89 ± 0.08.The fact that each compound plate was tested in triplicate and the screen used kinetic data rather than a simple end point may have contributed to the quality of this data set.
Signal-to-baseline characteristics
The signal-to-baseline (S:B) ratio in this kinetic assay was 134 ± 1 94 mAbs 348 units min -1 for all plates screened. This high S:B ratio was a result of the consistently large difference in the negative and positive controls on each plate (Fig. 1) . The negative controls had an average kinetic rate of 20.0 ± 7.5 mAbs 348 units min -1 , and the positive controls had an average value of 0.24 ± 0.15 mAbs 348 units min -1 . Consequently, strong CAIs could be easily identified by visual inspection of the assay plate or the raw data as shown for the known inhibitor, acetazolamide (Fig. 2) .
Enzyme and substrate stability
The CA II enzyme appeared to be stable and active over several hours, as verified by the high rate of 4-NPA esterase activity
,
, observed in the negative controls. The substrate showed significant background hydrolysis, despite the presence of 1.0 mM EDTA, thus requiring substrate replenishment every 15 min from a DMSO stock solution. Because of this relatively high background hydrolysis of 4-NPA, a high concentration of the CA II enzyme (1 µM) was used during screening to allow reliable measurement of activity. The concentration of substrate (0.4 mM) was within the typical range of 0.4 to 1.0 mM 4-NPA used in such assays 23, 25 and is far in excess of the enzyme concentration (1 µM). The substrate concentration is well below published K M values for this enzymesubstrate combination, which, because of 4-NPA's relatively low solubility in aqueous solutions, vary between 4 and 22 mM. 25, 26 The substrate concentration was chosen to be below K M to give the system the best possible chance to detect even weak competitive inhibitors of the system. 27 
Preliminary identification of hits
The assay was robust and detected known CA inhibitors, as demonstrated by the identification of acetazolamide and methazolamide ( Table 2 ). The initial screen yielded 19 hits, defined using an arbitrary cutoff of 48% inhibition ( Fig. 3; Table 2 ), indicating an initial hit rate of 2.0%. In addition to the 19 original hits, visual inspection of 3 additional compounds, identified by the percentage inhibition analysis, were disregarded because of noisy or inconsistent results: danazol, cyclophosphamide hydrate, and amphotericin B. The majority of hits identified by this analysis were sulfonamides, although several novel CAIs that did not have any sulfonamide groups were also identified.
An alternative analysis of the screening data was performed using a statistical analysis of the results. Compounds whose reaction rates were less than the mean plate value by 2 times the standard deviation (<2σ), for at least 2 of 3 duplicate assays, were identified as hits. This method yielded 25 hits, with a subset of 20 compounds that were consistently below the mean kinetic rate value by 2σ in 3 repeated runs (data not shown). This hit list included the 19 hits identified previously (with at least 48% inhibition) and 6 additional hits, pyrvinium pamoate, tolazamide, reserpine, estradiol proprionate, rifampin, and phenolphthalein, showing between 12% and 23% inhibition. However, there was significant variation in the activity of the 6 weaker hits, and so these compounds were not characterized further.
Hit confirmation and characterization
Before further characterization, the original 19 hits were first retested at a concentration of 18 µM in the original screening assay. Only 1 of the initial hits, cevadine, failed to show activity when retested and so was not further characterized. Characterization studies were then performed on the 18 confirmed hit compounds in Table 2 to confirm that they were specific, competitive inhibitors of the CA II enzyme and determine their potencies. These studies included determining inhibitor potencies using the esterase assay (see Fig. 4 ) and the equilibrium dissociation constant (K d value) using a competition binding assay with DNSA, as summarized in Table 1 . Additional experiments were performed to test if the active compounds were acting by some nonspecific or "promiscuous" mechanism. 21 These secondary assays included determining the IC 50 values by either testing for inhibition with a 5-fold higher enzyme concentration (5 µM) or in the presence of 0.01% Triton X-100, a nonionic detergent.
In addition, one of the nonsulfonamide hits was obtained from 2 different sources, Sigma-Aldrich and Microsource Discovery Systems, to evaluate any influence of supply on potency. An additional high-affinity CA II sulfonamide inhibitor, ethoxzolamide, and fluorescent but weak sulfonamide inhibitor, DNSA, were included in these characterization studies for comparison.
Results of IC 50 assays with 1 and 5 µ µM CA II
The hits were characterized by determining their potency in the esterase activity using 2 enzyme concentrations (Table 1), the rationale being that the measured IC 50 would remain unaltered if the compounds were acting by a specific mechanism. The results from these experiments were not consistent with the compounds acting by some nonspecific or promiscuous mechanism. The average IC 50 value for all compounds was 3.5-fold higher, including 3.3-fold and 6.0-fold higher values for the strong CA II inhibitors, acetazolamide and ethoxzolamide.
Merbromin yielded a relatively weak IC 50 value of 1.3 mM (Hill slope of 0.48) with 1 µM enzyme, but there is a large experimental uncertainty associated with this compound due to the failure to attain 100% inhibition in the IC 50 assays. The IC 50 value of merbromin decreased by 27-fold from 1.3 mM to 49 µM with 5 µM enzyme, and unexpectedly, the Hill slope increased to 9. However, as noted above, the IC 50 and Hill slope values for this compound have a large inherent uncertainty.
Hill slope as an indicator of promiscuity
Four of the sulfonamide compounds (acetazolamide, benzthiazide, ethoxzolamide, and methazolamide) exhibited Hill slopes closer to 2.0 than 1.0. These compounds had average Hill slopes of 2.2 ± 0.3 and 2.7 ± 0.7 in the presence or absence of Triton X-100 (1 µM CA II) and 3.4 ± 0.5 (5 µM CA II). Although they are not large deviations from 1.0, these observations contravene the rule of thumb that a Hill slope deviating from 1.0 is indicative of a poor lead, either a false hit or nonspecific promiscuous inhibitor, as reviewed earlier. 28 This rule of thumb is further confounded by the fact that tannic acid, a heterogeneous polyphenolic compound, described by the supplier as a promiscuous inhibitor, exhibited a Hill slope much closer to 1.0.
Results of an IC 50 assay with 1 µ µM CA II and Triton X-100
It has been suggested that addition of 0.01% to 0.1% Triton X-100 can help to discriminate between productive and nonspecific inhibitors. 21 Most of the hits exhibited similar potency in the esterase assay in the presence or absence of Triton X-100, suggesting the hits are specific inhibitors. The notable exception was tannic acid, which yielded an atypically large, 640-fold increase in the IC 50 value, consistent with its being a nonspecific inhibitor. Excluding tannic acid, the average IC 50 value for all compounds increased by 2.6-fold (±2.1-fold) in the presence of the detergent. Addition of Triton X-100 caused 8-to 10-fold increases in IC 50 values for thioxolone and merbromin, suggesting that these compounds may be functioning in some nonspecific, promiscuous manner.
Dissociation constant assay results
The dissociation constants (K d values) were determined for most of the potential hits using a competitive binding assay with a fluorescent sulfonamide, DNSA ( Table 1) . The K d values presented here are all similar to previously published values, for example, acetazolamide, 16 nM versus 11 nM; sulfanilamide, 13 µM versus 1 µM; and dansylamide, 2.7 µM versus 1 µM. Apparent binding constants, K i s, were calculated for the compounds using the Cheng-Prusoff equation 29 with IC 50 data for 1 µM CA II and the published K M of 4 mM for 4-NPA. The average K i for all compounds (excluding metolazone) was ∼7-fold higher than the average experimentally determined K d . This figure was biased by strong inhibitors, which gave up to 52-fold higher K i values. In general, the weaker inhibitors exhibited average K i values lower than those experimentally determined. This suggests that the Cheng-Prusoff equation underestimates the binding affinity of strong binders and overestimates the affinity of weak ligands in this assay. However, it should be noted that the substrate K M value was not experimentally determined for these assay conditions, but the general observation would hold true.
DISCUSSION
The majority of inhibitors identified in this study contain free sulfonamide groups, confirming the observation that sulfonamides are often CAIs. 11 In fact, many of the sulfonamides identified here are diuretics, a class of drugs recommended for the treatment of hypertension 30 and that have been shown to have CA inhibition as their primary target. 31 Similarly, celecoxib is a sulfonamide primarily used as a COX-2 inhibitor for the treatment of pain but may also have anticancer activity 32 and has been identified as a CAI. 15 Sulfonamide binding has been shown to involve direct coordination of the ionized nitrogen to the active site zinc. 5 This is consistent in that of the ∼40 secondary sulfonamide-linked compounds tested, none showed significant activity.
Sulfanilamide and mafenide are 2 hits categorized as antibacterials; indeed, sulfanilamide, a metabolite of the antibacterial prontosil, was the 1st CAI described in the literature. 33 Halazone is an atypical antimicrobial sulfonamide derivative also identified as a CAI in this study 34 and is reported to protect sodium channels from inactivation. 35 A literature search of the PubMed database fails to yield any mention of this compound as a CAI. However, as the function of this antimicrobial is to release chlorine, it is not clear if the chlorinated or chlorine-free sulfonamide form of this compound is actually inhibiting CA II; the free chloride anion is also a known inhibitor of CA II. 2, 5 Thus, it is possible that both free sulfonamide and any chloride degradation products of this compound inhibit the enzyme.
Four primary sulfonamide compounds were tested that did not significantly inhibit CA II: bendroflumethiazide, hydroflumethiazide, sulpiride, and bumetanide ( Table 3) . Three of these compounds are classified as diuretics and may target mammalian CA isozymes other than CA II. The remaining compound, sulpiride, is a dopamine receptor antagonist used as an antipsychotic, but it has been shown to bind CA-II by X-ray crystallography. 18 This work identified 3 potential CAIs not possessing any sulfonamide-related structural groups. Tannic acid is a large, heterogeneous, polyphenolic compound described as a "nonspecific enzyme/receptor blocker" by the compound supplier. Phenol is a well-known inhibitor of CA II 5 ; thus, terminal phenolic subunits or breakdown products of this compound may account for its activity. A search of various databases indicates that thioxolone has not previously been identified as a CAI. Merbromin (mercurochrome) is a fluorescein derivative used as a topical disinfectant that has not previously been reported to inhibit CA II. Merbromin contains a mercury ion that may coordinate to the imidazole side chain of His64 or the thiol side chain of Cys206 in the CA II active site; both residues have been observed to bind Hg 2+ ions.
36
Assay limitations
In this study, 2 mechanistically different assays were used to probe interactions with CA II. The 4-NPA esterase assay has been used in numerous studies to characterize the activity of CAs. This colorimetric kinetic absorbance assay is simple and robust, even for test compounds with significant background absorbance at the measured wavelength. However, this assay has at least 2 significant drawbacks: First, a robust assay signal requires the use of an enzyme concentration of 1 µM, which will limit the lower limit of affinity that can be reliably detected by this method. Second, the assay may not be useful for other CA isozymes (e.g., CA III) that have much lower rates of esterase activity. Although the nonphysiological esterase assay effectively identifies competitive inhibitors, it is probably not useful for identifying activators of the physiological CO 2 hydration/HCO 3 -dehydration reaction. A 2nd fluorescence intensity assay was used to characterize hits from the primary screen. This assay monitored binding of DNSA to CA II by the increase in fluorescence upon binding. Although the binding assay is performed under equilibrium conditions and thus avoids the need for kinetic analysis, it requires excitation of the probe at 280 nm, which made it unsuitable for primary screening. Numerous compounds, typically 3% to 5% of the samples, exhibited autofluorescence with this wavelength, yielding high background levels of fluorescence, as reported previously. 37 Thus, although the fluorescent intensity assay was expected to be more sensitive, in practice, the colorimetric kinetic assay proved to be more useful, and the fluorescence intensity assay was used for hit confirmation and characterization.
